Global Retirement Partners LLC Grows Stake in argenex SE $ARGX

Global Retirement Partners LLC raised its holdings in shares of argenex SE (NASDAQ:ARGX) by 582.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 730 shares of the company’s stock after buying an additional 623 shares during the period. Global Retirement Partners LLC’s holdings in argenex were worth $614,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. PSP Research LLC bought a new stake in shares of argenex during the fourth quarter valued at approximately $530,000. Intrust Bank NA raised its stake in argenex by 17.3% in the fourth quarter. Intrust Bank NA now owns 873 shares of the company’s stock worth $734,000 after buying an additional 129 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of argenex by 65.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the company’s stock worth $2,713,000 after purchasing an additional 1,280 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of argenex by 28.2% during the fourth quarter. Handelsbanken Fonder AB now owns 52,678 shares of the company’s stock worth $44,300,000 after purchasing an additional 11,573 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in shares of argenex by 17.9% during the fourth quarter. ProShare Advisors LLC now owns 1,286 shares of the company’s stock worth $1,081,000 after purchasing an additional 195 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ARGX. Guggenheim boosted their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Glj Research raised shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Finally, Oppenheimer decreased their price objective on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Trading Up 1.5%

ARGX stock opened at $820.63 on Thursday. The company has a market cap of $51.03 billion, a price-to-earnings ratio of 36.54, a PEG ratio of 1.28 and a beta of 0.46. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a 50-day moving average of $773.63 and a two-hundred day moving average of $815.24.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. As a group, equities analysts forecast that argenex SE will post 25.27 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.